CoChat
Sign Up
Cited by 66

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Immunotherapy in hepatocellular carcinoma

Buonaguro, Luigi, Mauriello, Angela, Cavalluzzo, Beatrice, Petrizzo, Annacarmen, Tagliamonte, Maria·2019·Annals of Hepatology
DOI 10.1016/j.aohep.2019.04.003
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.aohep.2019.04.003

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
Fig. 1 Combinatorial approach for HCC treatment. The available immunological approaches in HCC therapy are shown. A combination of them is foreseen to produce a dramatic increase in clinical outcome in HCC patients.
Fig. 1 Combinatorial approach for HCC treatment. The available immunological approaches in HCC therapy are shown. A combination of them is foreseen to produce a dramatic increase in clinical outcome in HCC patients.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 94

  1. Forner, 2018, Hepatocellular carcinoma, Lancet, 391, 1301, 10.1016/S0140-6736(18)30010-2 · DOI
  2. Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016/S0140-6736(02)08649-X · DOI
  3. Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 · DOI
  4. Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 · DOI · Paper page
  5. Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9 · DOI
  6. Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 · DOI · Paper page
  7. Eatrides, 2017, Role of systemic therapy and future directions for hepatocellular carcinoma, Cancer Control, 24, 10.1177/1073274817729243 · DOI
  8. Brandi, 2013, Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study, Oncologist, 18, 1256, 10.1634/theoncologist.2013-0093 · DOI
  9. Ballardini, 2010, Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma, Tumori, 96, 768, 10.1177/030089161009600521 · DOI
  10. Marinelli, 2013, Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases, Hepat Mon, 13, 10.5812/hepatmon.11721 · DOI
  11. Pardee, 2012, Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities, Oncoimmunology, 1, 48, 10.4161/onci.1.1.18344 · DOI
  12. Kapanadze, 2013, Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma, J Hepatol, 59, 1007, 10.1016/j.jhep.2013.06.010 · DOI
  13. Jenne, 2013, Immune surveillance by the liver, Nat Immunol, 14, 996, 10.1038/ni.2691 · DOI · Paper page
  14. Carambia, 2013, Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells, J Hepatol, 58, 112, 10.1016/j.jhep.2012.09.008 · DOI
  15. Schildberg, 2008, Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells, Eur J Immunol, 38, 957, 10.1002/eji.200738060 · DOI
  16. Thomson, 2010, Antigen-presenting cell function in the tolerogenic liver environment, Nat Rev Immunol, 10, 753, 10.1038/nri2858 · DOI
  17. You, 2008, Mechanism of T cell tolerance induction by murine hepatic Kupffer cells, Hepatology, 48, 978, 10.1002/hep.22395 · DOI
  18. Ormandy, 2005, Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma, Cancer Res, 65, 2457, 10.1158/0008-5472.CAN-04-3232 · DOI
  19. Dou, 2018, Hepatic dendritic cells, the tolerogenic liver environment, and liver disease, Semin Liver Dis, 38, 170, 10.1055/s-0038-1646949 · DOI
  20. Okrah, 2018, Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology, NPJ Precis Oncol, 2, 25, 10.1038/s41698-018-0068-8 · DOI
  21. Neuzillet, 2015, Targeting the TGFbeta pathway for cancer therapy, Pharmacol Ther, 147, 22, 10.1016/j.pharmthera.2014.11.001 · DOI
  22. Calderaro, 2016, Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features, Hepatology, 64, 2038, 10.1002/hep.28710 · DOI
  23. Dai, 2017, Positive expression of programmed death ligand 1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma, Transl Oncol, 10, 511, 10.1016/j.tranon.2017.03.009 · DOI
  24. Yan, 2015, Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages, Gut, 64, 1593, 10.1136/gutjnl-2014-307671 · DOI
  25. Li, 2012, Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma, Hepatology, 56, 1342, 10.1002/hep.25777 · DOI · Paper page
  26. Sideras, 2017, PD-L1 galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma, Oncoimmunology, 6, e1273309, 10.1080/2162402X.2016.1273309 · DOI
  27. Zhou, 2017, Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas, Gastroenterology, 153, 1107, 10.1053/j.gastro.2017.06.017 · DOI
  28. Budhu, 2006, Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment, Cancer Cell, 10, 99, 10.1016/j.ccr.2006.06.016 · DOI
  29. Nishida, 2017, Immunological microenvironment of hepatocellular carcinoma and its clinical implication, Oncology, 1, 40, 10.1159/000451015 · DOI
  30. Ganapathi, 2014, Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance, Br J Cancer, 111, 1581, 10.1038/bjc.2014.477 · DOI
  31. Kim, 2018, Association between expression level of PD1 by tumor-infiltrating CD8(+) T cells and features of hepatocellular carcinoma, Gastroenterology, 155, 1936, 10.1053/j.gastro.2018.08.030 · DOI
  32. Zhao, 2015, Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis, PLOS ONE, 10, e0139598, 10.1371/journal.pone.0139598 · DOI
  33. Hattori, 2003, Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma, Hepatol Res, 27, 309, 10.1016/j.hepres.2003.07.002 · DOI
  34. Liu, 2008, Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice, J Clin Invest, 118, 1165
  35. Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 · DOI · Paper page
  36. Liang, 2013, Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression, Br J Cancer, 109, 1031, 10.1038/bjc.2013.390 · DOI
  37. Sideras, 2015, Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area, Br J Cancer, 112, 1911, 10.1038/bjc.2015.92 · DOI
  38. Wang, 2015, Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma, Int J Clin Exp Pathol, 8, 3513
  39. Wang, 2019, Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes, Sci Rep, 9, 253, 10.1038/s41598-018-36319-x · DOI
  40. Giannakis, 2016, Genomic correlates of immune-cell infiltrates in colorectal carcinoma, Cell Rep, 15, 857, 10.1016/j.celrep.2016.03.075 · DOI
  41. Brown, 2014, Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival, Genome Res, 24, 743, 10.1101/gr.165985.113 · DOI
  42. Petrizzo, 2018, Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients, J Transl Med, 16, 286, 10.1186/s12967-018-1662-9 · DOI
  43. Kim, 2016, Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure), Ann Oncol, 27, 1492, 10.1093/annonc/mdw217 · DOI · Paper page
  44. Maleki, 2018, High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors, J Immunother Cancer, 6, 157, 10.1186/s40425-018-0479-7 · DOI · Paper page
  45. Greillier, 2018, The clinical utility of tumor mutational burden in non-small cell lung cancer, Transl Lung Cancer Res, 7, 639, 10.21037/tlcr.2018.10.08 · DOI
  46. Hendriks, 2018, Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy, Transl Lung Cancer Res, 7, 647, 10.21037/tlcr.2018.09.22 · DOI
  47. Fujimoto, 2016, Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer, Nat Genet, 48, 500, 10.1038/ng.3547 · DOI
  48. Bassani-Sternberg, 2016, Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry, Nat Commun, 7, 13404, 10.1038/ncomms13404 · DOI · Paper page
  49. Bassani-Sternberg, 2018, Mass spectrometry based immunopeptidomics for the discovery of cancer neoantigens, Methods Mol Biol, 1719, 209, 10.1007/978-1-4939-7537-2_14 · DOI
  50. Bulik-Sullivan, 2018, Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification, Nat Biotechnol
  51. Duan, 2014, Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity, J Exp Med, 211, 2231, 10.1084/jem.20141308 · DOI
  52. Luksza, 2017, A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy, Nature, 551, 517, 10.1038/nature24473 · DOI
  53. Rech, 2018, Tumor immunity and survival as a function of alternative neopeptides in human cancer, Cancer Immunol Res, 10.1158/2326-6066.CIR-17-0559 · DOI
  54. Sangro, 2013, A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, J Hepatol, 59, 81, 10.1016/j.jhep.2013.02.022 · DOI
  55. El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2 · DOI · Paper page
  56. Duffy, 2017, Phase I and preliminary phase II study of TRC105 in combination with sorafenib in hepatocellular carcinoma, Clin Cancer Res, 23, 4633, 10.1158/1078-0432.CCR-16-3171 · DOI
  57. Zhu, 2018, Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol, 19, 940, 10.1016/S1470-2045(18)30351-6 · DOI · Paper page
  58. Brown, 2017, Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer, J Immunother Cancer, 5, 93, 10.1186/s40425-017-0298-2 · DOI
  59. Mizukoshi, 2011, Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma, Hepatology, 53, 1206, 10.1002/hep.24149 · DOI
  60. Buonaguro, 2016, Developments in cancer vaccines for hepatocellular carcinoma, Cancer Immunol Immunother, 65, 93, 10.1007/s00262-015-1728-y · DOI
  61. Butterfield, 2003, T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer, Clin Cancer Res, 9, 5902
  62. Butterfield, 2006, A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides, Clin Cancer Res, 12, 2817, 10.1158/1078-0432.CCR-05-2856 · DOI
  63. Lee, 2005, Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial, J Immunother, 28, 496, 10.1097/01.cji.0000171291.72039.e2 · DOI
  64. Palmer, 2009, A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma, Hepatology, 49, 124, 10.1002/hep.22626 · DOI
  65. El, 2013, Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC, J Cancer Res Clin Oncol, 139, 39, 10.1007/s00432-012-1298-8 · DOI
  66. Greten, 2010, A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma, BMC Cancer, 10, 209, 10.1186/1471-2407-10-209 · DOI
  67. Sawada, 2012, Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival, Clin Cancer Res, 18, 3686, 10.1158/1078-0432.CCR-11-3044 · DOI · Paper page
  68. Buonaguro, 2017, New vaccination strategies in liver cancer, Cytokine Growth Factor Rev, 36, 125, 10.1016/j.cytogfr.2017.06.010 · DOI
  69. Zitvogel, 2008, The anticancer immune response: indispensable for therapeutic success?, J Clin Invest, 118, 1991, 10.1172/JCI35180 · DOI
  70. Ghiringhelli, 2007, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol Immunother, 56, 641, 10.1007/s00262-006-0225-8 · DOI
  71. Tesniere, 2010, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, 29, 482, 10.1038/onc.2009.356 · DOI
  72. Lake, 2005, Immunotherapy and chemotherapy – a practical partnership, Nat Rev Cancer, 5, 397, 10.1038/nrc1613 · DOI
  73. Lencioni, 2012, Local-regional treatment of hepatocellular carcinoma, Radiology, 262, 43, 10.1148/radiol.11110144 · DOI
  74. Chu, 2014, Thermal ablation of tumours: biological mechanisms and advances in therapy, Nat Rev Cancer, 14, 199, 10.1038/nrc3672 · DOI
  75. Nikfarjam, 2005, Mechanisms of focal heat destruction of liver tumors, J Surg Res, 127, 208, 10.1016/j.jss.2005.02.009 · DOI
  76. Haen, 2011, More than just tumor destruction: immunomodulation by thermal ablation of cancer, Clin Dev Immunol, 2011, 160250, 10.1155/2011/160250 · DOI
  77. Dromi, 2009, Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity, Radiology, 251, 58, 10.1148/radiol.2511072175 · DOI
  78. Zerbini, 2010, Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response, Gastroenterology, 138, 1931, 10.1053/j.gastro.2009.12.051 · DOI
  79. Schlom, 2007, Cancer vaccines: moving beyond current paradigms, Clin Cancer Res, 13, 3776, 10.1158/1078-0432.CCR-07-0588 · DOI
  80. Wheeler, 2004, Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination, Clin Cancer Res, 10, 5316, 10.1158/1078-0432.CCR-04-0497 · DOI
  81. Tagliamonte, 2016, A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice, J Transl Med, 14, 58, 10.1186/s12967-016-0812-1 · DOI
  82. Tagliamonte, 2015, Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model, Cancer Immunol Immunother, 64, 1305, 10.1007/s00262-015-1698-0 · DOI
  83. Audia, 2007, Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes, Clin Exp Immunol, 150, 523, 10.1111/j.1365-2249.2007.03521.x · DOI
  84. Laheru, 2008, Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation, Clin Cancer Res, 14, 1455, 10.1158/1078-0432.CCR-07-0371 · DOI
  85. Petrizzo, 2018, Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting, Oncotarget, 9, 3576, 10.18632/oncotarget.23181 · DOI
  86. Greten, 2010, Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC, J Immunother, 33, 211, 10.1097/CJI.0b013e3181bb499f · DOI
  87. Gameiro, 2013, Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression, PLOS ONE, 8, e70417, 10.1371/journal.pone.0070417 · DOI
  88. Liu, 2009, Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine, Mol Ther, 17, 2049, 10.1038/mt.2009.221 · DOI
  89. Sawada, 2016, Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients, Oncoimmunology, 5, e1129483, 10.1080/2162402X.2015.1129483 · DOI · Paper page
  90. Karyampudi, 2014, Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody, Cancer Res, 74, 2974, 10.1158/0008-5472.CAN-13-2564 · DOI
  91. Ali, 2016, Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication, Cancer Immunol Res, 4, 95, 10.1158/2326-6066.CIR-14-0126 · DOI
  92. Collins, 2018, Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy, Expert Rev Vaccines, 17, 697, 10.1080/14760584.2018.1506332 · DOI
  93. Tran, 2019, Therapeutic cancer vaccine: building the future from lessons of the past, Semin Immunopathol, 41, 69, 10.1007/s00281-018-0691-z · DOI
  94. McArthur, 2016, Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy, Clin Adv Hematol Oncol, 14, 922

Cited by

Sorted by citations

Metadata

Authors
Buonaguro, L., Mauriello, A., Cavalluzzo, B., Petrizzo, A., & Tagliamonte, M.
Venue
Annals of Hepatology
Publisher
Elsevier BV
Published
2019-03
Volume
18
Issue
2
Pages
291-297
ISSN
1665-2681
DOI
10.1016/j.aohep.2019.04.003
Cited by
66
References
9
Language
en
Licence
Funders
  • EU FP7 Project Cancer Vaccine development for Hepatocellular Carcinoma – HEPAVAC (602893)
  • HEPAVAC

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review